(AZN:London Stock Exchange)
Transactions by ASTRAZENECA PLC (AZN) in the last 6 months
Entasis Therapeutics announced that it has received $40 million in its series A round of funding from AstraZeneca PLC in March 2015.
AstraZeneca PLC (LSE:AZN) acquired Corridor Pharmaceuticals, Inc. from Acidophil, LLC, MedImmune Ventures, Inc. and other investors in 2014.
Domain Associates, L.L.C.
Domain Partners VI, L.P.
MedImmune Ventures, Inc.
Osage Partners LLC
Pharma San Isidro acquired Laboratorios Rontag S.A. from AstraZeneca PLC (LSE:AZN) for approximately ARS 10 million on February 24, 2015. The value of the transaction shall be payable in installments. The agreement comprises the transfer of all brands and registers.
|Abbott Laboratories||$50.21 USD||+0.47|
|BASF SE||€76.91 EUR||-0.50|
|Celgene Corp||$119.28 USD||+0.46|
|Eli Lilly & Co||$88.73 USD||+2.38|
|Valeant Pharmaceuticals International Inc||C$289.22 CAD||+3.01|
|View Industry Companies|